Fixed combination isosorbide dinitrate–hydralazine for nitric-oxide-enhancing therapy in heart failure
| Autor: | Joseph A Franciosa |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Drug
media_common.quotation_subject Management of heart failure Population Cardiac Output Low Isosorbide Dinitrate Pharmacology Nitric Oxide Nitric oxide chemistry.chemical_compound Humans Medicine Nitric Oxide Donors Pharmacology (medical) education media_common Heart Failure education.field_of_study business.industry General Medicine Hydralazine medicine.disease Drug Combinations chemistry Heart failure Isosorbide dinitrate business Isosorbide dinitrate/hydralazine medicine.drug |
| Zdroj: | Expert Opinion on Pharmacotherapy. 7:2521-2531 |
| ISSN: | 1744-7666 1465-6566 |
| DOI: | 10.1517/14656566.7.18.2521 |
| Popis: | The major advances in our understanding and management of heart failure (HF) in recent decades have not fully benefited all segments of our population. HF still represents a growing epidemic, especially for African-Americans, in whom the burden of HF is even greater. The recently reported beneficial effects of the fixed combination of isosorbide dinitrate and hydralazine (ISDN+HYD) in the African-American Heart Failure Trial (A-HeFT), has led to both the FDA approval of this agent and its endorsement by the latest HF guidelines. The properties of ISDN+HYD are well known as its components are mature agents, readily available in generic formulations that have been used for decades in other indications. However, fixed-dose ISDN+HYD represents the first drug to undergo targeted clinical development and to be approved for use in a specific ethnic group. As such, A-HeFT and the approval of ISDN+HYD represent landmark events that merit further scrutiny. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|